Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Azilsartan Medoxomil and Amlodipine Combined and Alone in Essential Hypertension
NCT05385770Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azilsartan medoxomil and amlodipine in essential hypertension (8 arms), sponsored by Celltrion. Primary endpoint: mean sitting Systolic Blood Pressure at 8 weeks. Started Jul 2022; status: completed.
02
Drugs
azilsartan medoxomilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05385770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385770.